Edition:
United Kingdom

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

8.60CAD
8:07pm GMT
Change (% chg)

$0.10 (+1.18%)
Prev Close
$8.50
Open
$8.51
Day's High
$8.69
Day's Low
$8.51
Volume
160,518
Avg. Vol
100,241
52-wk High
$8.81
52-wk Low
$7.38

Latest Key Developments (Source: Significant Developments)

Knight Therapeutics And Jaguar Health Announce Strategic Partnership
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND JAGUAR HEALTH ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS INC - TO BE RESPONSIBLE FOR ALL REGULATORY AND COMMERCIAL ACTIVITIES FOR MYTESI AND RELATED PRODUCTS IN LICENSED TERRITORIES.KNIGHT THERAPEUTICS - UPON ACHIEVEMENT OF REGULATORY, SALES MILESTONES IN AGREEMENT, JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION.KNIGHT THERAPEUTICS - AGREEMENT GRANTS CO EXCLUSIVE RIGHT TO COMMERCIALIZE MYTESI AND RELATED PRODUCTS IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - AGREEMENT GRANTS CO A RIGHT OF FIRST NEGOTIATION TO COMMERCIALIZE MYTESI & RELATED PRODUCTS IN SPECIFIED LATAM COUNTRIES.KNIGHT THERAPEUTICS INC - JAGUAR IS ALSO PURSUING POSSIBLE FOLLOW-ON INDICATIONS FOR MYTESI IN CANCER THERAPY-RELATED DIARRHEA.KNIGHT THERAPEUTICS - JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION THROUGHOUT INITIAL 15-YEAR TERM OF AGREEMENT.  Full Article

Knight Therapeutics Reports Q2 Basic EPS $0.028
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS REPORTS SECOND QUARTER 2018 RESULTS.QTRLY BASIC EARNINGS PER SHARE $ 0.028.QTRLY REVENUES $2.2 MILLION, DOWN 10 PERCENT.  Full Article

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND THERAPEUTICSMD ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS - CO, THERAPEUTICSMD ENTERED LICENSING AGREEMENT THAT GRANTS CO RIGHTS TO COMMERCIALIZE TX-004HR AND TX-001HR IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - WILL PAY THERAPEUTICSMD A MILESTONE FEE UPON FIRST REGULATORY APPROVAL IN CANADA OF EACH OF TX-004HR AND TX-001HR.KNIGHT THERAPEUTICS - AGREED TO INVEST $20 MILLION IN THERAPEUTICSMD COMMON STOCK ALONG WITH CLOSING OF PUBLIC OFFERING OF THERAPEUTICSMD COMMON STOCK.  Full Article

KNIGHT THERAPEUTICS REPORTS Q3 EARNINGS PER SHARE $0.03
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc :KNIGHT REPORTS THIRD QUARTER 2017 RESULTS.QTRLY ‍REVENUE $1.9 MILLION, A DECREASE OF 2 PERCENT​.QTRLY EARNINGS PER SHARE $0.03‍​.‍ALL CURRENCIES ARE CANADIAN​.  Full Article

Knight Therapeutics reports qtrly earnings per share $0.03‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc ::Knight reports third quarter 2017 results.Qtrly earnings per share $0.03.Q3 earnings per share view C$0.03 -- Thomson Reuters I/B/E/S‍​.Qtrly ‍revenues were $1.9 million, a decrease of 2 percent versus same period in prior year​.All currencies are Canadian‍​.  Full Article

Knight Therapeutics CFO Jeffrey Kadanoff steps down
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Knight Therapeutics Inc :Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017​.Effective immediately, Samira Sakhia, president of Knight, will assume additional responsibility of CFO​.  Full Article

Knight Therapeutics announces increase in ownership of Crescita Therapeutics
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Knight Therapeutics Inc :Knight Therapeutics - ‍pursuant to early warning requirements of national instrument 62-103, co announced increase in ownership of Crescita Therapeutics.Knight Therapeutics Inc - ‍now owns aggregate of 2.08 million common shares of crescita representing about 14.9 pct of outstanding common shares of Crescita​.  Full Article